Ancora Advisors LLC lifted its holdings in CVS Health Corp (NYSE:CVS) by 9.9% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 60,981 shares of the pharmacy operator’s stock after acquiring an additional 5,470 shares during the quarter. Ancora Advisors LLC’s holdings in CVS Health were worth $4,800,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in CVS. BlackRock Inc. lifted its holdings in shares of CVS Health by 5.9% in the 2nd quarter. BlackRock Inc. now owns 74,135,102 shares of the pharmacy operator’s stock worth $4,770,597,000 after acquiring an additional 4,121,620 shares during the last quarter. Charles Schwab Investment Advisory Inc. bought a new stake in CVS Health during the 2nd quarter valued at $190,701,000. Boston Partners raised its holdings in CVS Health by 41.9% during the 2nd quarter. Boston Partners now owns 9,908,888 shares of the pharmacy operator’s stock valued at $637,637,000 after buying an additional 2,924,875 shares during the last quarter. Morgan Stanley raised its holdings in CVS Health by 28.4% during the 2nd quarter. Morgan Stanley now owns 8,358,263 shares of the pharmacy operator’s stock valued at $537,854,000 after buying an additional 1,848,678 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec raised its holdings in CVS Health by 52.1% during the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 5,171,271 shares of the pharmacy operator’s stock valued at $332,771,000 after buying an additional 1,771,170 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.
A number of equities research analysts recently commented on CVS shares. Tigress Financial reiterated a “buy” rating on shares of CVS Health in a report on Friday, October 26th. Bank of America upped their price target on shares of CVS Health from $86.00 to $90.00 and gave the company a “buy” rating in a report on Monday, September 17th. Royal Bank of Canada set a $99.00 price target on shares of CVS Health and gave the company a “buy” rating in a report on Tuesday, October 23rd. Morgan Stanley set a $100.00 price target on shares of CVS Health and gave the company a “buy” rating in a report on Wednesday, November 7th. Finally, Argus upped their price target on shares of CVS Health to $100.00 and gave the company a “buy” rating in a report on Tuesday, November 13th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $90.69.
Shares of NYSE CVS opened at $74.09 on Friday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.44 and a quick ratio of 1.94. CVS Health Corp has a 12 month low of $60.14 and a 12 month high of $83.88. The firm has a market capitalization of $80.39 billion, a price-to-earnings ratio of 12.56, a P/E/G ratio of 1.13 and a beta of 0.98.
CVS Health (NYSE:CVS) last issued its quarterly earnings data on Tuesday, November 6th. The pharmacy operator reported $1.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.71 by $0.02. CVS Health had a net margin of 1.65% and a return on equity of 18.69%. The business had revenue of $47.27 billion during the quarter, compared to analyst estimates of $47.22 billion. During the same period in the prior year, the business earned $1.50 EPS. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. Equities research analysts expect that CVS Health Corp will post 7.03 EPS for the current year.
In other CVS Health news, CFO David M. Denton sold 25,159 shares of the company’s stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $80.13, for a total value of $2,015,990.67. Following the completion of the transaction, the chief financial officer now directly owns 403 shares in the company, valued at approximately $32,292.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Eva C. Boratto sold 13,311 shares of the company’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the completion of the transaction, the executive vice president now owns 55,162 shares of the company’s stock, valued at $4,256,299.92. The disclosure for this sale can be found here. Insiders sold a total of 74,233 shares of company stock valued at $5,932,565 over the last 90 days. Company insiders own 0.53% of the company’s stock.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Featured Story: Net Asset Value (NAV)
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.